Posted on 04/19/2022 5:50:18 AM PDT by Oldeconomybuyer
Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year.
The health care giant said Tuesday that a global supply surplus and demand uncertainty prompted the move, which will not affect the company’s operational earnings per share guidance.
J&J’s one-shot vaccine brought in $457 million in global sales during the first quarter, with most of that coming from outside the United States. The vaccine brought in only $75 million in sales in the U.S., or about 25% less than what it rang up after debuting in last year’s first quarter.
J&J has said it doesn’t intend to profit from the vaccine. But it said in January that it could bring in between $3 billion and $3.5 billion in sales this year, as countries continue to fight variants of the virus.
The vaccine brought in $2.38 billion in sales last year.
(Excerpt) Read more at apnews.com ...
Nuremberg justice now!
If they publicly have to scale back sales forecasts it will negatively impact the stock.
Plus it makes for “bad narrative”..
C’mon, people! We need you to get your fourth Booster!
In on this thread before the FR covid jab proselytizers start their haughty mocking and arrogantly telling us how they are so much smarter than the rest of us for getting 42 boosters to make sure they are protected from covid. Oh wait, none of the covid jabs actually protect you from getting it, spreading it or dying from it, but the way they tell it they are way smarter than us unvaccinated dullards!
BINGO!
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.